Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection

Current Opinion in Infectious Diseases
Alisdair A MacConnachie, W T Andrew Todd

Abstract

Shiga toxin producing Escherichia coli (STEC) cause a wide spectrum of disease ranging from asymptomatic carriage through to haemorrhagic colitis and the haemolytic uraemic syndrome. There are no current therapeutic interventions available in clinical practice that can prevent the development of haemolytic uraemic syndrome. A number of newly developed agents offer the potential for the treatment of STEC-associated disease. Three different classes of agent designed to bind and inactivate shiga toxin have now been developed. Synthetic toxin binders, recombinant bacteria and monoclonal antibodies provide potentially potent agents that could prevent the development of haemolytic uraemic syndrome. These agents have been shown in animal models of STEC disease to be effective. A recent clinical trial of one synthetic toxin binder showed no benefit in established haemolytic uraemic syndrome. More potent toxin binders, however, have since been developed and await human clinical trials. It is likely to be important that these agents are administered early in the course of disease in order to have maximum efficacy. Although rapid diagnostic techniques are available for the diagnosis of STEC disease, they still rely on stool culture. Clini...Continue Reading

References

Jul 17, 1998·Clinical Microbiology Reviews·J C Paton, A W Paton
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S DundasS J Hutchinson
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Kiyotaka NishikawaYasuhiro Natori
Sep 14, 2002·Infection and Immunity·Jean MukherjeeSaul Tzipori
Feb 25, 2003·The Journal of Infectious Diseases·George L MulveyGlen D Armstrong
Sep 11, 2003·JAMA : the Journal of the American Medical Association·Howard TrachtmanUNKNOWN Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial
Jan 28, 2004·The Journal of Infectious Diseases·Miho WatanabeKiyotaka Nishikawa
Feb 27, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A-C SjögrenD Karpman
Apr 30, 2004·The Journal of Infectious Diseases·Rebecca A PinyonRenato Morona

❮ Previous
Next ❯

Citations

Mar 7, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·Rakesh SehgalSunil Kumar
Nov 11, 2014·Foodborne Pathogens and Disease·Sukayna M FadlallahGhassan M Matar
Jul 7, 2012·Cellular and Molecular Life Sciences : CMLS·Andreas BauwensJohannes Müthing
Nov 29, 2007·Current Opinion in Gastroenterology·Antonio Serna, Edgar C Boedeker
Feb 25, 2005·Journal of the American Society of Nephrology : JASN·Marina Noris, Giuseppe Remuzzi
Nov 2, 2016·Critical Reviews in Microbiology·Charlotte CordonnierStéphanie Blanquet-Diot
May 22, 2020·Frontiers in Cellular and Infection Microbiology·Sabrina Mühlen, Petra Dersch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Lancet
Paul S Mead, Patricia M Griffin
The Journal of Infectious Diseases
Rebecca A PinyonRenato Morona
JAMA : the Journal of the American Medical Association
Howard TrachtmanInvestigators of the HUS-SYNSORB Pk Multicenter Clinical Trial
© 2021 Meta ULC. All rights reserved